Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia

• Register: ClinicalTrials.gov
• Last refreshed on: 20 September 2021
• Main ID: NCT02388048
• Date of registration: 09/03/2015
• Prospective Registration: Yes
• Primary sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
• Public title: Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia
• Scientific title: A Phase II Study of the Combination of Ofatumumab and Ibrutinib Followed by Allogeneic Bone Marrow Transplant or Consolidation for Pretreated High Risk Patients With Chronic Lymphocytic Leukemia
• Date of first enrolment: October 2015
• Target sample size: 19
• Recruitment status: Active, not recruiting
• URL: https://clinicaltrials.gov/show/NCT02388048
• Study type: Interventional
• Study design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
• Phase: Phase 2

Countries of recruitment

Italy

Contacts

• Name: Marco Montillo
• Affiliation: Department of Hematology, Niguarda Ca' Granda, Milan

• Name: Francesca R. Mauro
• Affiliation: Department of Hematology, Policlinico Umberto I di Roma

Key inclusion & exclusion criteria

Inclusion Criteria:

1. Male or female, age 18 years or until 65 years;

2. Confirmation of B-CLL previously treated with no more than 1 previous line of
treatment .

3. Risk patients with CLL defined as follows:

- treated patients showing 17p deletion in >20% of the cells by FISH, or TP53
mutation or,

- resistant (SD/PD) to fludarabine containing combination therapy or relapse within
12 months from a fludarabine-containing combination therapy.

4. Active disease meeting at least 1 of the following IWCLL criteria for requiring
treatment:

- Evidence of progressive marrow failure as manifested by the development of, or
worsening of anemia (Hb< 10 g/dL) and/or thrombocytopenia (platelets <
100,000/mL).

- Massive (= 6 cm below the left costal margin), progressive, or symptomatic
splenomegaly.

- Massive nodes (at least 10 cm longest diameter), or progressive or symptomatic
lymphadenopathy.

- Progressive lymphocytosis with an increase of more than 50% over a 2-month period
or a lymphocyte doubling time (LDT) of < 6 months.

- Autoimmune hemolytic anemia and/or immune thrombocytopenia that is poorly
responsive to corticosteroids or other standard therapy.

- One or more disease-related symptoms:

- unintentional weight loss > 10% within 6 months prior to screening;

- significant fatigue (inability to work or perform usual activities);

- fevers >38.0°C for 2 or more weeks prior to screening;

- night sweats for more than 1 month prior to screening.

5. Stage B or C of CLL according to Binet staging system;

6. Stage A disease fitting the criteria for treatment according to the IWCLL-NCI criteria
(2008) are also included.

7. WHO performance status 0-II.

8. Life expectancy = 6 months.

9. Hematology values must be within the following limits:

- Absolute neutrophil count (ANC) = 750/mm3 independent of growth factor support;

- Platelets =100,000/mm3 or = 30.000/mm3 if bone marrow involvement independent of
transfusion support in either situation.

10. Biochemical values within the following limits:

- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 3 x upper
limit of normal (ULN).

- Total bilirubin = 1.5 x ULN unless bilirubin rise is due to Gilbert's syndrome or
of non-hepatic origin.

- Serum creatinine = 2 x ULN or estimated Glomerular Filtration Rate (Cockroft
Gault) = 30 mL/min/1.73m2.

11. Women of childbearing potential and men who are sexually active must be practicing a
highly effective method of birth control during and after the study For females, these
restrictions apply for 1 month after the last dose of ibrutinib and for 12 months
after the last dose of Ofatumumab. For males, these restrictions apply for 3 months
after the last dose of ibrutinib. Men must agree to not donate sperm during and after
the study.

12. Women of childbearing potential must have a negative serum (beta-human chorionic
gonadotropin [ß-hCG]) or urine pregnancy test at Screening. Women who are pregnant or
breastfeeding are ineligible for this study.

13. Sign an informed consent document indicating that they understand the purpose of and
procedures required for the study, including biomarkers, and are willing to
participate in the study.

Exclusion Criteria:

1. Major surgery within 3 weeks before registration.

2. Known central nervous system lymphoma.

3. History of stroke or intracranial hemorrhage within 6 months prior to registration.

4. Requires anticoagulation with warfarin or equivalent vitamin K antagonists (eg,
phenprocoumon).

5. Clinically significant cardiovascular disease such as uncontrolled or symptomatic
arrhythmias, congestive heart failure, or myocardial infarction within 6 months of
Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by
the New York Heart Association Functional Classification.

6. Vaccinated with live, attenuated vaccines within 4 weeks of registration.

7. Known history of human immunodeficiency virus (HIV) or active Hepatitis C Virus or
active Hepatitis B Virus infection or any uncontrolled active systemic infection
requiring intravenous (IV) antibiotics.

8. Any life-threatening illness, medical condition, or organ system dysfunction which, in
the investigator's opinion, could compromise the subject's safety, interfere with the
absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue
risk.

9. Positive serology for Hepatitis B (HB) defined as a positive test for HBsAg. In
addition, if negative for HBsAg but HBcAb positive (regardless of HBsAb status), a
HBDNA test will be performed and if positive the subject will be excluded. ***see
attached monitoring criteria for HBcAb+ and HBV DNA negative subjects.

10. Other past or current malignancy. Subjects who have been free of malignancy for at
least 5 years, or have a history of completely resected non-melanoma skin cancer, or
successfully treated in situ carcinoma are eligible.

11. Requirement for treatment with a strong CYP3A4/5 and/or CYP2D6 inhibitor.

12. Significant concurrent, uncontrolled medical condition including, but not limited to,
renal, hepatic, gastrointestinal, endocrine, pulmonary, neurological, cerebral or
psychiatric disease which in the opinion of the investigator may represent a risk for
the patient.

13. Inability to swallow capsules or tablets, or disease significantly affecting
gastrointestinal function and/or inhibiting small intestine absorption.

14. Chronic or current infectious disease requiring systemic antibiotics, antifungal, or
antiviral treatment such as, but not limited to, chronic renal infection, chronic
chest infection with bronchiectasis, tuberculosis.

15. Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura.

16. Central nervous system involvement with CLL.

17. Subjects who have current active hepatic or biliary disease (with exception of
patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable
chronic liver disease per investigator assessment).

18. Treatment with any known non-marketed drug substance or experimental therapy within 5
terminal half lives or 4 weeks prior to enrollment, whicheve


Age minimum: 18 Years
Age maximum: 65 Years
Gender: All

Health Condition(s) or Problem(s) studied

Leukemia, Lymphoblastic, Chronic

Intervention(s)

Drug: Ibrutinib + ofatumumab

Primary Outcome(s)

The number of pretreated patients with high risk CLL who achieve a Complete Response (CR) after the induction therapy with Ibrutinib plus Ofatumumab. [Time Frame: After 6.5 years from treatment start]

Secondary Outcome(s)

Number of patients alive [Time Frame: At 60 months from treatment start]

Number of patients in Complete Response (CR)/Partial Response (PR) [Time Frame: After 28 weeks from treatment start]

Number of adverse events [Time Frame: At 6.5 years after treatment start]

Number of Minimal Residual Disease-negative Complete Responses [Time Frame: At 28 weeks from treatment start]

Number of patients without events [Time Frame: At 60 months from treatment start]

Number of patients without progression of the disease. [Time Frame: At 60 months from treatment start]

Secondary ID(s)

2015-000684-13

LLC1215

Source(s) of Monetary Support

Please refer to primary and secondary sponsors